Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 29Expanded_access 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Metastatic Castration-resistant Prostate Cancer 1

Interventions

gallium 68 PSMA-11 4Magnetic Resonance Spectroscopy 4Abiraterone Acetate 3carbon-11 acetate 2Prednisone 2Prednisolone 2Axitinib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zenocutuzumab 1ulixertinib 1trametinib 1tempol 1tazemetostat 1talazoparib 1radium Ra 223 dichloride 1pegilodecakin 1omburtamab I-131 1niraparib 1neratinib 1motexafin gadolinium 1enfortumab vedotin 1dodecyl maltoside 1bicalutamide 1bemarituzumab 1balstilimab 1atezolizumab 1apalutamide 1TEMPOL-H 1Suspensions 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × niraparib × Genitourinary × Clear all
NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Janssen Research & Development, LLC

Approved for marketing
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡